This edition of CNS Spectrums focuses on geriatric psychiatry and the current developments in the field that are expanding the physician's knowledge and ability to treat mental disorders in the elderly population. We will highlight four areas of interest in the field with four simple questions: (1) What is the evidence for the role of cerebrovascular disease in the pathogenesis and characteristics of late-life depression? (2) Medical burden can clearly contribute to and complicate the course of late-life depression, but how can its effect be measured? (3) How do we understand treatment-resistant depression in late life, and what are the best alternative approaches to seeking full remission? and (4) Now that we have amassed a great deal of experience using cholinergic-enhancing therapies, how do we understand their mechanisms of action and potential usefulness for other neuropsychiatric conditions in addition to Alzheimer's disease?
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New Horizons for Mental Health Care in the Elderly Population
By Mark D. Miller, MD
This edition of CNS Spectrums focuses on geriatric psychiatry and the current developments in the field that are expanding the physician's knowledge and ability to treat mental disorders in the elderly population. We will highlight four areas of interest in the field with four simple questions: (1) What is the evidence for the role of cerebrovascular disease in the pathogenesis and characteristics of late-life depression? (2) Medical burden can clearly contribute to and complicate the course of late-life depression, but how can its effect be measured? (3) How do we understand treatment-resistant depression in late life, and what are the best alternative approaches to seeking full remission? and (4) Now that we have amassed a great deal of experience using cholinergic-enhancing therapies, how do we understand their mechanisms of action and potential usefulness for other neuropsychiatric conditions in addition to Alzheimer's disease?
In the first article, Jeffrey Lyness, MD, surveys the literature on the cerebrovascular model of depression in late life with a critical focus on how the imaging and epidemiological evidence supports the cerebrovascular model of depression with respect to onset, course-concomitant cognitive dysfunction, and response to treatment. The implication of these findings for treatment options are briefly discussed.
Next, Helen Lavretsky, MD, and colleagues present an interesting and powerful approach to the study of multiple putative variables as risk factors for late-life depression using the Classification and Regression Tree Analysis (CART) technique. This method measures the interaction of variables, creating a resulting hierarchy of risk factors or risk factor combinations that are the most salient contributors for a defined threshold of pathology. Their focus on cerebrovascular risks, overall medical burden, and cognitive impairment are the very factors most often presenting a confusing mix of symptoms in clinical practice with depressed elders. The initial section of this paper is a succinct review of the role of medical burden and cerebrovascular disease in late-life depression as well as the interplay impact of cognitive dysfunction.
The rationale and methodology of the CART model of statistical analysis is clearly explained in detail. One intriguing result found was the interaction between the finding of frontal lobe atrophy and hyperintensity lesion volume as risk factors only when a certain threshold was achieved. The potential power of the CART methodology, it seems to me, could well be applied to the same data set collected at other centers to test the replicabilty of these interesting findings.
Having reviewed risk factors for late-life depression, now let us turn to treatment. Alastair Flint, MB, provides a thorough review of treatment-resistant depression in late-life. He clearly defines the term "treatment resistant," advocates stepping back to review the diagnosis, particularly whether early dementia is a cofactor, defines "adequate treatment," reviews medical comorbidity, and finally, discusses the pros and cons of augmentation, switching antidepressants, electroconvulsive therapy, and the experimental treatments of repetative transcranial magnetic stimulation and vagus nerve stimulation.
Turning to the article by Daniel Kaufer, MD, cholinesterse-inhibitor (ChEI) therapy may seem like switching gears from the topic of depression to dementia but, in fact, Kaufer's argument for the broader use of these agents lies in the assembled body of evidence he has collected to support a cholinergic-monaminergic continuum. Kaufer begins with a thorough review of the anatomy and pharmacology of the cholinergic system, the evidence for cholinergic deficits in AD, and the rational for using ChEI to combat that deficit. Kaufer goes on to review a broader array of neuropsychiatric symptoms that respond to ChEI therapy which, he argues, makes the case for the rationale use of ChEI in other dementias, including vascular dementia. Finally, Kaufer synthesizes his intriguing understanding of the "fit" of cholinergic function in the large sphere of overall brain function that justifies more trials of ChEI for use in a broader group of disorders than was originally thought.
In this issues' final report, Seppo Kahkonen, MD, PhD, describes a case of trichotillomania in a patient with schizophrenia who responded to augmentation of risperidone with citalopram. Kahkonen discusses differences in prevalence of trichotillomania across psychiatric disorders, and briefly reviews treatment options.
This issue of CNS Spectrums is an exciting representative cross-section of the advancement taking place in the field of geriatric psychiatry. Herein we attempt to better understand the pathophysiology of dementia and depression in later life and strive for more specific and targated therapies for the subclassifications of these debilitating disorders. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of escitalopram, caution should be exercised when LEXAPRO™ and lithium are coadministered. Sumatriptan -There have been rare pcstmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised. Theophylline -Combined administration of racemic citalopram (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetics of citalopram was not evaluated. Warfarin -Administration of 40 mg/day racemic citalopram for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine -Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of escitalopram should be considered if the two drugs are coadministered, 
LEXAPRO™
(escitalopram oxalate) TABLETS limited in vivo data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cma> and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. Metoprolol -Administration of 20 mg/day LEXAPRO™ for 21 days resulted in a 50% increase in Cmax and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioseiectivity. Coadministration of LEXAPRO™ and metoprolol had no clinically significant effects on blood pressure or heart rate. £lectroconvuIsive Therapy (ECT) -There are no clinical studies of the combined use of ECT and escitalopram. Pregnancy Pregnancy Category C In a rat embyro/fetal development study, oral administration of escitalopram (56,112 or 150 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased fetal body weight and associated delays in ossification at the two higher doses (approximately > 56 times the maximum recommended human dose [MRHO] of 20 mg/day on a body surface area [mg/nf] basis. Maternal toxicity (clinical signs and decreased body weight gain and food consumption), mild at 56 mgAg/day, was present at all dose levels. The developmental no effect dose of 56 mg/kg/day is approximately 28 times the MRHD on a mg/m ! basis. No teratogenicity was observed at any of the doses tested (as high as 75 times the MRHD on a mg/nf basis). When female rats were treated with escitalopram (6,12,24, or 48 mg/kg/day) during pregnancy and through weaning, slightly increased offspring mortality and growth retardation were noted at 48 mg/kg/day which is approximately 24 times the MRHD on a mg/m ! basis. Slight maternal toxicity (clinical signs and decreased body weight gain and food consumption) was seen at this dose. Slightly increased offspring mortality was seen at 24 mg/kg/day. The no effect dose was 12 mg/kg/day which is approximately 6 times the MRHD on a mg/nf basis. In animal reproduction studies, racemic citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses. In two rat embryo/fetal development studies, oral administration of racemic citalopram (32,56, or 112 mg/kg/day] to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose. This dose was also associated with maternal toxicity (clinical signs, decreased BW gain). The developmental no effect dose was 56 mg/kg/day. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of racemic citalopram of up to 16 mg/kg/day. Thus, teratogenic effects of racemic citalopram were observed at a maternally toxic dose in the rat and were not observed in the rabbit. When female rats were treated with racemic citalopram (4.8,12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose. The no effect dose was 12.8 mg/kg/day. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses ;>24 mg/kg/day. A no effect dose was not determined in that study. There are no adequate and well-controlled studies in pregnant women; therefore, escitalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Labor and Delivery The effect of LEXAPRO™ on labor and delivery in humans is unknown. Nursing Mothers Racemic citalopram, like many other drugs, is excreted in human breast milk. There have been two reports of infants experiencing excessive somnolence, decreased feeding, and weight loss in association with breast feeding from a citalopram-treated mother; in one case, the infant was reported to recover completely upon discontinuation of citalopram by its mother and, in the second case, no follow up information was available, The decision whether to continue or discontinue either nursing or LEXAPRO™ therapy should take into account the risks of citalopram exposure for the infant and the benefits of LEXAPRO™ treatment for the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Approximately 6% of the 715 patients receiving escitalopram in controlled trials of LEXAPRO™ in major depressive disorder were 60 years of age or older; elderly patients in these trials received daily doses of LEXAPRO™ between 10 and 20 mg. The number of elderly patients in these trials was insufficient to adequately assess for possible differential efficacy and safety measures on the basis of age. Nevertheless, greater sensitivity of some elderly individuals to effects of LEXAPRO™ cannot be ruled out. In two pharmacokinetic studies, escitalopram half-life was increased by approximately 50% in el-derly subjects as compared to young subjects and Cma!< was unchanged (see Clinical Pharmacology). 10 mg/day is the recommended dose for elderly patients (see Dosage and Administration). Of 4422 patients in clinical studies of racemic citalopram, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall differences in safety or effectiveness were observed betweenthese subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but again, greater sensitivity of some elderly individuals cannot be ruled out. ADVERSE REACTIONS Adverse event information for LEXAPRO™ was collected from 715 patients with major depressive disorder who were exposed to escitalopram and from 592 patients who were exposed to placebo in double-blind, placebocontrolled trials. An additional 284 patients were newly exposed to escitalopram in open-label trials. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and tabulations that follow, standard World Health Organization (WHO) terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. Adverse Events Associated with Discontinuation of Treatment Among the 715 depressed patients who received LEXAPRO™ in placebo-controlled trials, 6% discontinued treatment due to an adverse event, as compared to 2% of 592 patients receiving placebo. In two fixed dose studies, the rate of discontinuation for adverse events in patients receiving 10 mg/day LEXAPRO™ was not significantly different from the rate of discontinuation for adverse events in patients receiving placebo. The rate of discontinuation for adverse events in patients assigned to a fixed dose of 20 mg/day LEXAPRO™ was 10% which was significantly different from the rate of discontinuation for adverse events in patients receiving 10 mg/day LEXAPRO™ (4%) and placebo (3%). Adverse events that were associated with the discontinuation of at least 1% of patients treated with LEXAPRO™, and for which the rate was at least twice the placebo rate, were nausea (2%) and ejaculation disorder (2% of male patients). Incidence of Adverse Events in Placebo-Controlled Clinical Trials Table 1 enumerates the incidence, rounded to the nearest percent, of treatment emergent adverse events that occurred among 715 depressed patients who received LEXAPRO™ at doses ranging from 10 to 20 mg/day in placebo-controlled trials. Events included are those occurring in 2% or more of patients treated with LEXAPRO™ and for which the incidence in patients treated with LEXAPRO™ was greater than the incidence in placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied. The most commonly observed adverse events in LEXAPRO™ patients (incidence of approximately 5% or greater and approximately twice the incidence in placebo patients) were insomnia, ejaculation disorder (primarily ejaculatory delay], nausea, sweating increased, fatigue, and somnolence (see TABLE 1 ). 
LEXAPRO™ (escitalopram oxalate) TABLETS
* Events reported by at least 2% of patients treated with LEXAPR0'" are reported, except for the following events which had an incidence on placebo > LEXAPRO™: headache, upper respiratory tract infection, back pain, pharyngitis, inflicted injury, anxiety. Primarily ejaculatory delay. Denominator used was for males only (N=225 LEXAPRO™: N=188 placebo). 'Denominator used was for females only (N-490 LEXAPRO™: N=404
placebo). Dose Dependency of Adverse Events
The potential dose dependency of common adverse events (defined as an incidence rate of * 5% in either the 10 mg or 20 mg LEXAPRO™ groups] was examined on the basis of the combined incidence of adverse events in two fixed dose trials. The overall incidence rates of adverse events in 10 mg LEXAPRO™ treated patients (66%) was similar to that of the placebo treated patients (61%), while the incidence rate in 20 mg/day LEXAPRO™ treated patients was greater (86%]. Male and Female Sexual Dysfunction with SSRIs Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling are likely to underestimate their actual incidence. Table 2 shows the incidence rates of sexual side effects in patients with major depressive disorder in placebo controlled trials. 
<1%
There are no adequately designed studies examining sexual dysfunction with escitalopram treatment. Priapism has been reported with all SSRIs. While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects. Vital Sign Changes LEXAPRO™ and placebo groups were compared with respect to (1} mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with LEXAPRO™ treatment. In addition, a comparison of supine and standing vital sign measures in subjects receiving LEXAPRO™ indicated that LEXAPRO™ treatment is not associated with orthostatic changes. Weight Changes Patients treated with LEXAPRO™ in controlled trials did not differ from placebo-treated patients with regard to clinically important change in body weight. Laboratory Changes LEXAPRO™ and placebo groups were compared with respect to (1] mean change from baseline in various serum chemistry, hematology, and urinalysis variables and (2] the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with LEXAPRO™ treatment. ECG Changes Electrocardiograms from LEXAPRO™ (N=625), racemic citalopram (N=351), and placebo (N=527) groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed (11 a decrease in heart rate of 21 bpm for LEXAPRO™ and 2.7 bpm for racemic citalopram, compared to an increase of 0.3 bpm for placebo and (2] an increase in OTc interval of 3.9 msec for LEXAPRO™ and 3.7 msec for racemic citalopram, compared to 0.5 msec for placebo. Neither LEXAPRO™ nor racemic citalopram were associated with the development of clinically significant ECG abnormalities.
Other Events Observed During the Premarketing Evaluation of LEXAPRO™ Following is a list ot WHO terms that reflect treatment-emergent adverse events, as defined in the introduction to the ADVERSE REACTIONS section, reported by the 999 patients treated with LEXAPRO™ for periods of up to one year in double-blind or open-label clinical trials during its premarketing evaluation.
All reported events are included except those already listed in Table 1 , those occurring in only one patient, event terms that are so general as to be uninformative, and those that are unlikely to be drug related. It is important to emphasize that, although the events reported occurred during treatment with LEXAPRO™, they were not necessarily caused by it. Events are further categorized by body system and listed in order of decreasing frequency according to the following definitions: frequent adverse events are those occurring on one or more occasions in at least 1/100 patients; infrequent adverse events are those occurring in less than 1/100 patients but at least 1/1000 patients. In placebo-controlled trials of Celexa,some of which included patients with bipolar disorder, activation of mania/tiypomania was reported in 0,2% of 1063 patients treated with Celexa and in none of the 446 patients treated with placebo. Activation of mania/hypomania has also been reported in a small proportion of patients with major affective disorders treated with other marketed antjdepressants. As with all antidepressants, Celexa should be used cautiously in patients with a history of mania. Seizures Although anticonvulsant effects of citalopram have been observed in animal studies, Cefexa has not been systematically evaluated in patients with a seizure disorder. These patients were excluded from clinical studies during the product's premarketing testing, in clinical trials of Celexa, seizures occurred in 0.3% of patients treated with Celexa (a rate of one patient per 98 years of exposure) and 0.5% of patients treated with placebo {a rate of one patient per 50 years of exposure). Like other antidepressants, Celexa should be introduced with care in patients with a history of seizure disorder. Suicide Trie possibility of a suicide attempt is inherent in depression and may persist until significant remission occurs. Close supervision of high-risk patients should accompany initial drug therapy. Prescriptions for Celexa should be written for the smallest quantity of tablets consistent wrtti good patient management, in order to reduce the risk of overdose. Interference With Cognitive and Motor Performance In studies in normal volunteers, Celexa in doses of 40 mg/day did not produce impairment of intellectual function or psychomotor performance. Because any psychoactjve drug may impair judgement, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that Celexa therapy does not affect their ability to engage in such activities. Use in Patients With Concomitant Illness Clinical experience with Celexa in patients with certain concomitant systemic illnesses is limited. Caution is advisable in using Celexa in patients with diseases or conditions that produce altered metabolism or hemodynamic responses. Celexa has not been systematically evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Patients with these diagnoses were generally excluded from clinical studies during the product's premarketing testing, However, the electrocardiograms of 1116 patients who received Celexa in clinical trials were evaluated, and the data indicate that Celexa is not associated witti the development of clinically significant ECG abnormalities. In subjects with hepatic impairment, citalopram clearance was decreased and plasma concentrations were increased. The use of Celexa in hepatically impaired patients should be approached with caution and a lower maximum dosage is recommended. Because citalopram is extensively metabolized, excretion of unchanged drug in urine is a minor route of elimination. Until adequate numbers of patients with severe renal impairment have been evaluated during chronic treatment witti Celexa, however, it should be used with caution in such patients. Drug Interactions CMS DrugsGiven the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs. Alcohol -Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended. Monoamine Qxidase Inhibitors (MAOI's) -See CONTRAINDICATIONS and WARNINGS. Cimetidine -In subjects who had received 21 days of 40 mo/day Celexa, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and C^ of 43% ant) 39%, respectively. The clinical significance of these findings is unknown. Digoxin -In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin-Lithium -Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium. Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to die lithium dose in accordance with standard clinical practice. Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered. Theophylline -Combined administration of Celexa (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline. The effect of theophylline on the pharmacokinetjcs of citalopram was not evaluated. Sumatriptan -There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoodination following the use of a selective serotonin reuptake inhibitor (SSRI} and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (eg, fluoxeo'ne, fluvoxamine, paroxetine, sertraRne, citalopram) is clinically warranted, appropriate observation of the patient is advised. Warfarin -Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate. Prothrombin time was increased by 5%, the clinical significance of which is unknown. Carbamazepine -Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate. Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered. Adverse Events Occurring at an Incidence of 2% or More Among Celexa-Treated Patients TABLE 2 enumerates the incidence, rounded to the nearest percent, of treatment-emergent adverse evente that occurred among 1063 depressed patients who received Celexa at closes ranging from 10 to 80 mg/day in placebo-controlled trials of up to 6 weeks in duration. Events included are those occurring in 2% or more of patients treated with Ceiexa and for which the incidence in patients treated with Celexa was greater than the incidence in placebo-treated patients. The prescriber should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis tor estimating the relative contribution of drug and nondrug factors to the adverse event incidence rate in the population studied. The only commonly observed adverse event mat occuired in Celexa patients with an incidence of 5% or greater and at least twice the incidence in placebo patients was ejaculation disorder (primarily ejaculatory delay) in male patients (see constipation, palpitation, vision abnormal, steep disorder, nervousness, pharyngitis, micturition disorder, back pain.' Denominator used was for females only (N=638 Celexa; N=252 placebo). ? Primarily ejaculatory delay. 3 Denominator used was for males only (N=425 Celexa; N=194 placebo). Dose Dependency of Adverse Events The potential relationship between the dose of Celexa administered and the incidence of adverse events was examined in a fixeddose study in depressed patients receiving placebo or Celexa 10, 20, 40, and 60 mg.
Jonckheere's trend test revealed a positive dose response {p<.Q5) for the following adverse evente: fatigue, impotence, insomnia, sweating increased, somnolence, and yawning. Male and Female Sexual Dysfunction With SSRI's Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of ptiarmacologic treatment. In particular, some evidence suggests that selective serotonin re-uptake inhibitors (SSRIs) can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling, are likely to underestimate their actual incidence. The table below displays the incidence of sexin trolled clinical trials in patients with depression. In female depressed patients receiving Celexa, the reported incidence of decreased libido and anorgasmia was 1.3% (n=638 females) and 1.1% (n=252 females}, respectively. There are no adequately designed studies examining sexual dysfunction with citalopram treatment. Priapism has been reported with all SSRIs. While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRI's, physicians should routinely inquire about such possible side effects. Vital Sign Changes Celexa and placebo groups were compared with respect to (1) mean change from baseline in vital signs (pulse, systolic blood pressure, and diastolic blood pressure) and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses did not reveal any clinically important changes in vital signs associated with Celexa treatment. In addition, a comparison of supine and standing vital sign measures for Celexa and placebo treatments indicated that Celexa treatment is not associated with orthostatic changes. Weight Changes Patients treated with Celexa in controlled trials experienced a weight loss of about 0.5 kg compared to no change for placebo patients. Laboratory Changes Celexa and placebo groups were compared with respect to (1} mean change from baseline in various senjm chemistry, hematology, and urinalysis variables and (2) the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. These analyses revealed no clinically important changes in laboratory test parameters associated with Celexa treatment. ECG Changes Electrocardiograms from Celexa (N=802) and placebo (N=241) groups were compared with respect to (1) mean change from baseline in various ECG parameters and (2} the incidence of patients meeting criteria for potentially clinically significant changes from baseline in these variables. The only statistically significant drug-placebo difference observed was a decrease in heart rate for Celexa of 1.7 bpm compared to no change in heart rate for placebo. There were no observed differences in QT or other ECG intervals.
Treatment
Other Events Observed During the Premarketing Evaluation of Celexa
Following is a list of WHO terms that reflect treatment-emergent adverse events, as defined in the introduction to the ADVERSE REACTIONS section, reported by patients treated with Celexa at multiple doses in a range of 10 to 80 mg/day during any phase of a trial within the premarketing database of 4422 patients. All reported events are included except those already listed in TABLE
